← back to search

Yves Chalandon

University of Geneva · CH
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, and Chronic Myeloid Leukemia Treatments.
h-index
50
citations
11,458
works
482
NIH funding
primary concept
email

Recent publications

CNS manifestations in acute and chronic graft-versus-host disease
Brain 2024cited by 16position: middledoi
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Leukemia 2024cited by 10position: middledoi
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
The Lancet Haematology 2023cited by 24position: middledoi
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Leukemia 2023cited by 22position: middledoi
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Bone Marrow Transplantation 2021cited by 39position: lastdoi
GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation
Journal of Cancer Research and Clinical Oncology 2021cited by 6position: middledoi
Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation
Journal of Cancer Research and Clinical Oncology 2021cited by 1position: middledoi
GSTM1 and GSTT1 Double Null Genotypes Determining Cell Fate and Proliferation as Potential Risk Factors of Relapse in Children with Hematological Malignancies after Stem Cell Transplantation.
Research Square 2021cited by 1position: middledoi
GSTM1 and GSTT1 Double Null Genotypes Determining Cell Fate and Proliferation as Potential Risk Factors of Relapse in Children With Hematological Malignancies After Stem Cell Transplantation. On Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation
Research Square 2021cited by 0position: middledoi
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT
British Journal of Haematology 2020cited by 6position: middledoi
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Haematologica 2019cited by 67position: middledoi
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Haematologica 2019cited by 54position: middledoi
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Biology of Blood and Marrow Transplantation 2019cited by 33position: lastdoi
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
British Journal of Haematology 2019cited by 22position: middledoi
Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
Blood 2019cited by 1position: middledoi
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
JAMA Oncology 2018cited by 166position: middledoi
Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
Bone Marrow Transplantation 2018cited by 43position: middledoi
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <scp>EBMT</scp>
British Journal of Haematology 2018cited by 35position: middledoi
GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
Oncotarget 2017cited by 68position: middledoi
Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
British Journal of Haematology 2017cited by 52position: middledoi
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research
Biology of Blood and Marrow Transplantation 2016cited by 60position: middledoi
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Blood 2015cited by 371position: firstdoi
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Blood 2015cited by 268position: middledoi
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
British Journal of Haematology 2015cited by 109position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Henrique Bittencourt · Centre Hospitalier Universitaire Sainte-Justine5 papers (2017–2021)Jaap Jan Boelens · Weill Cornell Medicine5 papers (2017–2021)Nicolaus Kröger · Universität Ulm5 papers (2015–2019) · 5 papers (2017–2021)Jean‐Hugues Dalle · Centre National de la Recherche Scientifique5 papers (2017–2021)Christina Peters · Nottingham City Hospital5 papers (2017–2021)Jürgen Finke · University of Education Freiburg5 papers (2015–2019) · 5 papers (2017–2021) · 5 papers (2017–2021) · 4 papers (2021–2021) · 4 papers (2021–2021)Nicolas Waespe · Hospital for Sick Children4 papers (2021–2021) · 4 papers (2021–2021)Selim Corbacioglu · University of Regensburg4 papers (2021–2021)Marc Ansari · Western General Hospital4 papers (2017–2021)Johan Maertens · Ospedale Policlinico San Martino3 papers (2018–2019) · 3 papers (2021–2021) · 3 papers (2015–2019)Nicolaas Schaap · National Institute of Allergy and Infectious Diseases3 papers (2017–2019)Marie Robin · Université Claude Bernard Lyon 13 papers (2015–2019)